ReviewExploration (Beijing, China)2022
Nanotechnology-facilitated vaccine development during the coronavirus disease 2019 (COVID-19) pandemic.
Review in Exploration (Beijing, China), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Size-Dependent Neutralization Efficacy of Nanodecoys Against SARS-CoV-2 Mimics in Mammalian Cell Infection Models.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Review
- Inflammatory mediators of mRNA vaccine-induced adverse reactions in mice.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- mRNA Cancer Vaccines: From Pandemic Paradigm to Personalized Oncology Therapeutics.Cancer innovation · 2025Review
- Nanoparticle technologies in precision oncology and personalized vaccine development: Challenges and advances.International journal of pharmaceutics: X · 2025Review
- Emerging strategies for monkeypox: antigen and antibody applications in diagnostics, vaccines, and treatments.Military Medical Research · 2025Review
- Facile Synthesis of Lecithin-Sophorolipid Liponiosomes Encapsulating SARS-CoV‑2 Proteins for Therapeutic Applications.ACS omega · 2025Article
- The potential of plant-derived vesicles in treating periodontitis and associated systemic diseases: current advances and future directions.Journal of nanobiotechnology · 2025Review
- Deep learning-based classification of traditional Chinese medicine: a novel approach.Quantitative imaging in medicine and surgery · 2025Article
- Intelligent Batch Epitope Identification and Partitioning: an intelligent tool for the identification of B cell dominant epitopes.Briefings in bioinformatics · 2025Article
- Applications of flexible materials in health management assisted by machine learning.RSC advances · 2025Review
- Engineering a bivalent nanoparticle vaccine with PCV2 capsid protein and PRRSV epitopes.Journal of nanobiotechnology · 2025Article
- Why do lipid nanoparticles target the liver? Understanding of biodistribution and liver-specific tropism.Molecular therapy. Methods & clinical development · 2025Review
- Intramuscular All-Trans Retinoic Acid-Adjuvanted Nanovaccine Elicits Robust Mucosal and Systemic Immunity AgainstInternational journal of nanomedicine · 2025Article
- IntegratedCurrent medicinal chemistry · 2025Article
- Engineering a spleen-selective mRNA-LNPs vaccine by decoupling the inflammation from cellular immunity-mediated cancer immunotherapy.Theranostics · 2025Article
- Fc-empowered exosomes with superior epithelial layer transmission and lung distribution ability for pulmonary vaccination.Bioactive materials · 2024Article
- Aggregation-Induced Emission Luminogen: Role in Biopsy for Precision Medicine.Chemical reviews · 2024Review
- Rational design of a DNA-launched live attenuated vaccine against human enterovirus 71.Virologica Sinica · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (COVID-19) continually poses a significant threat to the human race, and prophylactic vaccination is the most potent approach to end this pandemic. Nanotechnology is widely adopted during COVID-19 vaccine development, and the engineering of nanostructured materials such as nanoparticles has opened new possibilities in innovative vaccine development by improving the design and accelerating the development process. This review aims to comprehensively understand the current situation and prospects of nanotechnology-enabled vaccine development against the COVID-19 pandemic, with an emphasis on the interplay between nanotechnology and the host immune system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.